This slide deck provides an overview of product introduction, the process of moving products to the “real world”— an interrelated set of actions needed for global and national health systems to incorporate and deliver new, improved or underused technologies.
Product Introduction for Advocates
Basic Elements of Product Introduction for HIV Prevention
What’s New & Next in HIV Prevention
A quick but comprehensive slideshow review by AVAC Executive Director Mitchell Warren reviewing the state of HIV prevention, forthcoming products, and what needs to come next. Much accomplished; much to do.
HIV Vaccines: The basics
This introductory PowerPoint slide set reviews basic concepts, and provides an overview of research status and recent developments.
The Evolution of Oral PrEP Access
A presentation on global trends in PrEP uptake since 2016, prepared for R4P. See breakdowns by country and analysis of lessons learned and continued use.
The Next-Generation of Biomedical Prevention: Now What
Slides presented by AVAC Executive Director Mitchell Warren at the PEPFAR Scientific Advisory Board meeting taking place over October 7-8, 2020.
A Roadmap for Results: Understanding the ECHO Study Results
On June 13, FP2020 and AVAC held a webinar, A Roadmap for Results: Understanding the ECHO Study Results, with the ECHO team following the results announcement. The webinar explained the trial, provided topline results, outlined next steps, and offered key advocacy messages to help all stakeholders understand the findings.
Watch here.
Hormonal Contraception and HIV Risk: Understanding the ECHO trial
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.
Results, expected in mid-2019, will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.
The webinar featured:
Beth Schlachter, Executive Director, FP2020
Dr. Jared Baeten, Vice Chair, Department of Global Health, University of Washington, ECHO Consortium
Dr. Nelly Mugo, Research Associate Professor, Global Health, University of Washington, ECHO Management Committee
Tamar Abrams, Communications Director, FP2020
You may view the webinar here.
HIV Vaccine Research and Development Pipeline: 2019 Supplement
A slide deck overview of what’s happening in HIV vaccine research now.
Oral PrEP Enrollment Snapshot
For trends in oral PrEP uptake, check out the Oral PrEP Enrollment Snapshot. This PowerPoint deck illustrates major findings from the tracker with heat maps showing where people are initiating PrEP, updates against targets and more. A PDF version is also available.
From Research to Roll Out: Comparing oral PrEP to the dapivirine ring
These slides provide an overview of the process that takes an HIV prevention product from the final phases of research into the real world where it’s broadly available. Also included is a comparison of findings from research on the dapivirine ring and oral PrEP at key points along the process.
A PDF version is also available.